|
Novartis Heart-Failure Drug Reduces Deaths in Phase III Study
Novartis’ experimental heart failure drug RLX030 reduced deaths in patients with acute heart failure (AHF) in a Phase III study, setting it up for a 2013 regulatory submission.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives